- Global Pharma News & Resources

CTI BioPharma to Present at Oppenheimer's 29th Annual Healthcare Conference on Tuesday, Mar. 19

SEATTLE, March 12, 2019 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at Oppenheimer's 29th Annual Healthcare Conference at 4:30 p.m. EDT at the Westin New York Grand Central.

Presentation details:


Oppenheimer's 29th Annual Healthcare Conference


Tuesday, Mar. 19


4:30 p.m. EDT

The presentation will be webcast live and available for replay from the Investors section of CTI BioPharma's website at

About CTI BioPharma Corp.

CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers. The CTI BioPharma lead product candidate, pacritinib, is being developed for the treatment of patients with myelofibrosis. CTI BioPharma is headquartered in Seattle, Washington.  For additional information and to sign up for email alerts and get RSS feeds, please visit

CTI BioPharma Investor Contacts:
Argot Partners
Maeve Conneighton/Maghan Meyers  



View original content to download multimedia:

SOURCE CTI BioPharma Corp.

Editor Details

Last Updated: 12-Mar-2019